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Abstract   24 
Microprolactinomas are the most common pituitary adenomas. In symptomatic patients, 25 
dopamine agonists are the first treatment of choice; when cabergoline is used, biochemical 26 
control rates between 85 and 93% have been reported. Long-term treatment is needed in most 27 
of the cases with compliance, patient convenience and potential adverse effects representing 28 
areas requiring attention. Based on the literature published in the last 15 years, 29 
transsphenoidal surgery can lead to normal prolactin in the post-operative period in usually 30 
71-100% of the cases with very low post-operative complication rates. Surgical expertise is 31 
the major determinant of the outcomes and it may be a cost-effective option in young patients 32 
with life expectancy greater than ten years (provided it is performed by experienced surgeons 33 
at high volume centres with confirmed optimal outcomes). Larger series of patients with 34 
adequate follow-up could further validate the place of transsphenoidal surgery (particularly 35 
through the endoscopic approach for which long-term results are currently limited) in the 36 
management algorithm of patients with microprolactinoma.  37 
 38 
Abbreviations: DA: Dopamine agonist, PRL: Prolactin 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
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I. Introduction 47 
Prolactinomas are the most common pituitary adenomas accounting for 51-66% of 48 
these tumours; recent epidemiological studies suggest prevalence 44-62 cases/100,000 49 
population (1). The median age at diagnosis is 32 years with 76-81% of them being 50 
microadenomas (1,2). The clinical manifestations of microprolactinomas are attributed to 51 
PRL excess and include galactorrhoea and those of hypogonadotropic hypogonadism. The 52 
main aims of their treatment include normalization of PRL and amelioration of the clinical 53 
consequences of the hyperprolactinaemia, prevention of tumour growth, as well as 54 
improvement of the quality of life. The adoption of a treatment option with the highest 55 
success rate, less side effects/complications and optimal cost-effectiveness is of major 56 
importance. Currently, dopamine agonists (DA) are the first line therapy for symptomatic 57 
microprolactinomas and transsphenoidal surgery is recommended to symptomatic patients 58 
who cannot tolerate high doses of cabergoline or who are not responsive to DA therapy (3). 59 
Resistance to DA includes a failure to achieve normal PRL on maximally tolerated 60 
doses of DA and a failure to achieve tumour shrinkage more than 50% (4). The second 61 
criterion would be considered clinically important mainly for macroprolactinomas due to 62 
their potential to exert pressure effects to surrounding structures. Decreased number of 63 
dopamine receptors 2 (D2) has been reported in DA resistant prolactinomas but the 64 
mechanism of DA resistance has not been completely elucidated (3,4).   The prevalence of 65 
resistance to DA treatment differs between the various agonists and has is less common in 66 
microprolactinomas and in women (3,5,6). The reported rates of PRL normalization in 67 
patients with microprolactinoma are around 57% with bromocriptine and 85-93% with 68 
cabergoline (5-8) with the latter agent leading to normoprolactinaemia in a significant 69 
number of bromocriptine resistant patients (4). A recent meta-analysis suggested that 70 
persisting normoprolactinaemia after withdrawal of DA is expected in only 21% of the cases 71 
with the probability been higher when cabergoline had been used for at least two years and 72 
pituitary MRI had shown normal appearances prior to DA discontinuation (9,10). Side 73 
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effects of these agents are mainly gastrointestinal with nausea and vomiting, as well as 74 
headaches and drowsiness; these can be minimized by gradual titration of the dose offered at 75 
bed time. Mood alterations (anxiety and depression), psychosis or behavioural changes 76 
including impulse control disorders may also occur and are considered to be reversible when 77 
the medication is stopped (4,11). Discontinuation of treatment due to intolerance has been 78 
described in 4% of the cases on cabergoline and 12% on bromocriptine (6,7). Although a 79 
clinically concerning association between the use of DAs for the treatment of 80 
hyperprolactinaemia and cardiac valvulopathy is not supported by the recently published 81 
literature (12), concerns remain on the impact of long-term use of cabergoline, even in low 82 
weekly doses, resulting in large cumulative doses.  83 
A systematic review of the outcomes of surgery specifically in patients with 84 
microprolactinomas based on the contemporary published literature is not available. Given 85 
the advances in transsphenoidal surgical techniques, and especially the minimally invasive 86 
ones, that have taken place in the last years, such an analysis is of major importance and will 87 
facilitate therapeutic decisions relying on existing evidence. We have, therefore, reviewed 88 
the available literature on the surgical management of microprolactinomas (microscopic and 89 
endoscopic) published between 2000 and 2015 and we have extensively assessed the data on 90 
biochemical remission and recurrence rates, predictive factors of recurrence, peri-operative 91 
complications and cost implications.   92 
 93 
II. Transsphenoidal surgery for microprolactinomas 94 
Surgery for microprolactinomas is currently performed through the transsphenoidal 95 
route with a microscope, endoscope or both. The endoscopic endonasal approach - a 96 
minimally invasive technique offering superior panoramic view and the benefits of avoiding 97 
submucosal transseptal dissection (thereby eliminating nasoseptal perforations), as well as 98 
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less patient discomfort due to the lack of nasal packing - has been applied in the latest years 99 
with less available published literature.  100 
 101 
i) Remission and recurrence rates after transsphenoidal surgery  102 
A summary of the surgical success rates from 45 studies published between 1977-103 
2005 (84.4% of them prior 2000) showed high variability in the achievement of normal PRL 104 
(38-100%) possibly reflecting differences in the neurosurgical expertise; the remission rate, 105 
as estimated based on the total number of included patients, was 74.7% and the recurrence of 106 
hyperprolactinaemia (affected by the variable definitions of cure/recurrence, observation 107 
periods and drop-out rates) was 18.2% (4). Studies published during the period covered in 108 
this review on patients with microprolactinoma treated with the microscopic transsphenoidal 109 
technique and with main indications resistance/intolerance to DAs or patient’s choice 110 
suggest that biochemical remission with normoprolactinaemia is achieved usually in 71-93% 111 
of the cases; serum PRL had been checked shortly after or within the first weeks following 112 
surgery (13-24) (Table 1). In a large series of 400 patients treated by the sublabial 113 
transsphenoidal approach by a single neurosurgeon, post-operative remission was reported in 114 
82% of the cases; information on previous treatment with DAs was not available (14). 115 
Raverot et al. in a collaborative multicenter study of 43 patients who stopped the DAs one 116 
month prior to the operation found a 93% remission rate (18). In two series with 46 (20) and 117 
59 (24) patients operated on by two experienced neurosurgeons in a single center, early 118 
postoperative normoprolactinaemia was reported in 91% and 78% of the cases, respectively; 119 
DAs had been stopped before surgery [at least four weeks in the first and at least two months 120 
(in almost half of the patients) in the second study]. Mortini et al. in a series of 69 patients 121 
operated on in a single centre by two surgeons (21), showed post-operative remission rate 122 
75% (off DA for at least two months).  Lower post-operative remission rates (40-63%) have 123 
been reported in three series with, however, small number of patients (5, 27 and 32) 124 
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affecting the estimation of the relevant rates (25-27). Most studies with mean/median 125 
follow-up period ranging between 12 and 84 months suggest that recurrence of the 126 
hyperprolactinaemia is observed between 0 and 13% of the cases (15-17,20,23). In one 127 
study, however, recurrence rate of 33% was described during a median observation period of 128 
33 months (22). It should be noted that information on the timing of stopping DA treatment 129 
was not available in this report and the possibility that the rate of early biochemical 130 
remission may also reflect the impact of DA cannot be excluded.  131 
Series reporting the outcomes of endoscopic transsphenoidal surgery in 132 
microprolactinomas are rather limited (Table 2). The post-operative remission rates range 133 
between 81-100% and in all but one of the studies there is no available information on 134 
previous DA administration (19,28-35). Given that the main advantages of the endoscopic 135 
approach involve invasive adenomas, it would be anticipated that the remission rates should 136 
not differ between microscopic and endoscopic techniques in microprolactinomas. 137 
Recurrence rate of 0% has been described in two series with 7 (32) and 12 (34) patients 138 
within a median follow-up period of 62 months and 15 months, respectively. Tanei et al. 139 
(29) reported relapse rate of 25% but this relies on a group of only 4 patients.  140 
Series confirming that the operations were carried out by one or two surgeons in a 141 
single center or by surgeons each performing 80 pituitary operations per year, mostly show 142 
higher remission rates (82-100%) (13-16,18,20,30-32) pointing out the importance of 143 
surgical expertise. Other factors affecting biochemical remission are not clearly defined 144 
specifically for the microprolactinomas as the reported results include analyses for both 145 
micro- and macroprolactinomas. Tamasauskas et al. (26) suggested that lack of pre-146 
operative therapy with DAs was an independent factor associated with optimal surgical 147 
outcome in microprolactinomas; perivascular fibrosis in the adenoma (36) introduced by the 148 
medical treatment was a possible mechanism. However, a number of series including both 149 
micro- and macroprolactinomas did not confirm this finding (13,16,24,25). The pre-150 
operative PRL levels have been negatively associated with remission in all types of 151 
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prolactinomas (16,20,24,25,27); nonetheless, the impact of previous DA treatment on the 152 
PRL values used for the statistical analyses is not clear. Finally, Primeau et al., (25) in a 153 
series of 63 patients operated on for a prolactinoma (43% micro-), showed that absence of 154 
adenoma tissue on MRI performed 3 months post-operatively was positively related with 155 
remission of the hyperprolactinaemia.    156 
Main drawbacks of the published literature include the small number of patients and 157 
the short observation period in many series (particularly the endoscopic ones), as well as the 158 
variable protocols for the confirmation of biochemical remission and detection of recurrence 159 
(timing of blood sampling after surgery, duration of stopping DAs). Furthermore, the 160 
specific indications for surgery may have introduced a bias in the selection of patients 161 
studied; the impact of this (positive or negative) in the reported outcomes is not clear. 162 
Finally, the available literature may not necessarily reflect the “real life” outcomes, as the 163 
published data tend to represent experience of large centers with usually optimal results. 164 
 165 
ii) Peri- and post-operative complications in microprolactinomas 166 
The reported peri- and post-operative complications in microscopic series include 167 
mortality 0% (13,15-17,19-22,24,27), visual deterioration 0% (13,15,27) and other 168 
neurosurgical complications 0-1.8% (febrile sinusitis, epistaxis requiring emergency nasal 169 
tamponade and  mucocele requiring evacuation one year later) (20,24). Outcomes of 170 
pituitary function are shown in Table 3 and in all (15,19,20,22,24,26) but one (with a very 171 
small number of patients) (23) studies they look rather optimal; hypogonadism or permanent 172 
diabetes insipidus were found between 0 and 6%.  173 
The reported peri- and post-operative complications in endoscopic series include 174 
mortality 0% (19,29-31,33-35,37), visual deterioration 0% (32,34,37) and other 175 
neurosurgical complications 0% (37). Outcomes of pituitary function are shown in Table 3; 176 
Page 7 of 20
8 
 
new pituitary hormone deficits range between 0 and 6% (19,29,30,37). Notably, no cases of 177 
permanent diabetes insipidus have been described.    178 
 179 
iii) Quality of life and costs 180 
Data on the quality of life of patients with microprolactinomas treated by surgery are 181 
not currently available.  182 
Based on a study from the UK published in 1999 (38), the costs for a hypothetical 183 
patient with microprolactinoma undergoing surgery and cure with no complications and 184 
followed-up for 10 years did not differ from those required for a patient receiving 185 
cabergoline 1 mg/week for 10 years. 186 
In a very recently published study (39) Jethwa et al. performed a cost-effectiveness 187 
analysis comparing transsphenoidal surgery (microscopic or endoscopic) and medical 188 
therapy (bromocriptine or cabergoline) in microprolactinomas using decision analysis 189 
modelling. Each probability (cure rates, complications) in the model was based on data 190 
gathered from the published literature and costs were taken from the perspective of the US 191 
healthcare third-party payer. Base case analysis revealed that medical therapy was more 192 
costly and less effective than surgery in young patients with life expectancy greater than 10 193 
years. The authors propose that the costs of medications continue to accumulate with time, 194 
whereas the costs of surgery are realized upfront and do not recur on a continuous basis, 195 
unless the patient has post-operative hypopituitarism requiring hormone replacement 196 
therapy. They point out though that the operation should be performed only by experienced 197 
surgeons at high volume centers with optimal biochemical cure and low complications rates. 198 
It should be noted, however, that in this study a number of assumptions had to be made in 199 
order to complete the model; these may not be a perfect reflection of the real world, thereby 200 
introducing errors and may not necessarily apply to different medical economic 201 
environments in other countries.   202 
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 203 
III. Conclusions and Future Perspectives 204 
In the last decades, medical treatment has been considered the mainstay in the 205 
management of microprolactionomas. This relies on the well established high biochemical 206 
control and low drug intolerance rates (particularly for cabergoline, 85-93% and 4%, 207 
respectively) leading physicians to overlook the option of surgical removal and often not to 208 
discuss this with the patient at the time of diagnosis.  Based on the literature published in the 209 
last 15 years and keeping in mind its limitations as described above, surgery by experienced 210 
hands can achieve biochemical control in 82-100% of the cases with practically minimum 211 
complication rates; amongst them, permanent diabetes insipidus (up to 6%) is probably the 212 
one requiring more attention. The reported recurrence rates (derived mostly from 213 
microscopical transsphenoidal operations) need to be taken into account, although at present, 214 
they do not seem to be particularly high (mostly 0-13%).  215 
Therefore, in centers with neurosurgical expertise in which the chance of successful 216 
and safe removal of a symptomatic microprolactinoma can be high, the adoption of this 217 
route is not an unreasonable approach and needs at least to be discussed with the patient or 218 
even offered as primary therapy to selected, suitable patients. This is of particular relevance 219 
for young patients with a favourable surgical target who may require decades of medical 220 
therapy or for those non-compliant to DA treatment (provided surgery is not complicated by 221 
hypopituitarism requiring replacement). 222 
Areas that need to be further clarified in this field include the impact of longer 223 
observation periods on sustaining biochemical remission and the timing of recurrence (if 224 
detected long after the operation allowing a female to reach menopause, it may not be of 225 
clinical significance). Such data should be generated from large series of non-selected (if 226 
possible) patients followed-up by robust protocols. Also, quality of life, financial strains on 227 
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patients and their families and cost-effectiveness issues remain to be elucidated. Finally, 228 
further outcomes of endoscopic surgery in microprolactinomas are eagerly awaited. 229 
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Table 1. Outcomes of series including patients with microprolactinoma treated by the 1 
microscopic transsphenoidal approach. 2 
Ref. Total 
N 
Age (yrs) 
(range) 
 
Males 
N 
Age (yrs) 
(range) 
 
Females 
N 
Age (yrs) 
 
Indications 
for surgery 
Follow-up 
(months) 
(range) 
N of patients 
with remission of 
hyperPRLaemia 
post-operatively 
(%) 
N of patients with 
recurrence of 
hyperPRLaemia 
(%) 
 (13) 21 
All <40 
0 21 
 
DA resistance 
or intolerance 
Patient’s 
preference 
Intratumoural 
haemorrhagea 
Mean 
144a 
18 (86%)b - 
 (14)  400 - - - - 328 (82%)c - 
 (25) 27 0 27 
Mean 26±7 
DA resistance 
or intolerance 
Patient's 
preference 
Mean 
75±59 
17 (63%)d 4/17 (24%)d 
(26) 32 0 32 
Mean 31±8 
DA resistance 
or intolerance 
Patient's 
preference 
Mean 
50±32 
19 (59%)e - 
(15) 24 
Median 30  
(18-52) 
4 
Median 39  
(18-52) 
 
20 
Median 29  
(18-46) 
Patient’s 
preference 
(no DA 
previously) 
Median 
30 
(6-77) 
22 (91%) 0/22 (0%) 
(16) 18 18 
Median 38 
(17-69)a 
0 DA resistance 
or intolerance 
Tumour 
apoplexy 
Patient's 
preference 
Median  
45 
(13-121)a 
15 (83%)f 
 
2/15 (13%)f 
  
(17) 
12 
Median 32  
(17 - 65)a 
- 
 
DA resistance 
or intolerance 
Patient's 
preference   
Tumour 
apoplexy a 
Mean  
39 
(1-62)a 
11 (92%)g 1/11 (9%)g 
 (18)  43 
Mean 38±13a 
- 
 
DA resistance 
or intolerance 
Patient's 
preference 
Mean 
138 ± 46a 
40 (93%)h -  h 
(19) 21 - - Mean  
61 
(1 – 144)i 
15  (71%)j - 
(20)  46 
Median 32 
(12-69)a 
- DA resistance 
or intolerance 
Patient's 
preference a 
Median  
12 
(3–132)a 
42 (91%)k 3/42 (7%)k 
(21) 69 
Mean 30±1a 
- - Mean 
53±4a 
52 (75%)m - 
(22)  20 
Mean 33±3a 
- 
 
DA resistance 
or  intolerance 
Patient's 
Median  
33a 
15 (75%) 5/15 (33%)n 
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preference a 
(23)    11 11 
Median 41 
(32 - 54) 
0 - Median 
84  
(24-156) 
8 (73%) 0/8 (0%) 
  
(27) 
5 
Median 31a 
- DA resistance  
or  intolerance 
Patient's 
preferencea 
Mean 
44i 
2 (40%)p 1/2 (50%)p 
(24) 59 
Mean 30±1  
(12-67)a 
- 
 
DA resistance  
or  intolerance 
Patient's 
preference 
Mean  
50±3 
(1-132)a 
46 (78)q - q 
 3 
In the above series the authors report microscopic or do not confirm endoscopic approach. 4 
 5 
a: Data for both micro- and macroprolactinomas. 6 
b: PRL was measured 7-10 days, 6 months and 1-5 years after surgery. The patients were instructed to visit the 7 
hospital in case of menstrual irregularities. Information of timing of stopping the DA prior to surgery not available. 8 
c: The authors use the term “cured microprolactinomas” and no further details are provided. Information on 9 
previous DA treatment not reported. 10 
d: Remission was defined as normoprolactinaemia without any treatment for at least 6 months post-operatively. 11 
Recurrence was defined as the re-detection of hyperprolactinemia 6 months or longer after surgery (if the 12 
recurrence occurred within the first 6 months, patients were not considered to have had remission). 13 
e: Information of timing of stopping the DA prior to surgery not available. 14 
f: Remission was defined as normal PRL without DA for at least 4 weeks before surgery. Recurrence was based on 15 
detection hyperprolactinaaemia during the follow-up period.  16 
g: Remission post-operatively was defined as normal PRL on day 7 post-operatively off DA for at least 6 weeks 17 
before surgery. Remission during long-term follow-up was defined as normal PRL in the absence of DA treatment 18 
for 3 months. Follow-up data were available for 12 patients with microprolactinomas and these have been included 19 
in the Table.  20 
h: DA treatment was stopped one month prior to surgery. Serum PRL was measured 1-2 weeks after surgery and 21 
yearly for at least 10 years. Long-term follow-up data specifically for microprolactinomas are not reported. 22 
i:  Data for all adenomas included in this series.  23 
j:  Remission was defined as normalization of PRL checked at least 6 weeks post-operatively and after withdrawal 24 
of  DA within the same period. 25 
k:  Remission was defined as normal PRL on day 7 post-operatively (off DA therapy for at least 4 weeks prior to 26 
surgery). Recurrence was defined as hyperprolactinaemia at last follow-up; long-term data were available for 46 27 
patients and these have been included in the Table.  28 
m:  Remission was defined normalization of PRL off DA for at least 2 months. PRL levels had to remain normal 29 
for a minimum of 6 months, otherwise patients were not included in the remission group. Data on long-term 30 
remission specifically for microprolactinomas are not reported. 31 
n:  Information of timing of stopping the DA prior to surgery not available. Recurrence of hyperprolactinaemia 32 
occurred within 4 years after surgery. 33 
p:  DAs were stopped the day before surgery. Remission was defined as the resolution of hyperprolactinaemia 34 
three months post-operatively.  35 
q:  Remission was defined as normalization of PRL measured 5-6 days after surgery. If patients had received DA 36 
or had discontinued this shortly before surgery, the earlier postoperative value used for classifying surgical 37 
outcome was that obtained at least 2 months after surgery. Patients were not considered in remission if 38 
hyperprolactinaemia recurred within 6 months of surgery. Follow up data specifically for microprolactinomas are 39 
not reported. 40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
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Table 2. Outcomes of series including patients with microprolactinoma treated by the 1 
endoscopic transsphenoidal approach (as confirmed by the authors of the papers). 2 
Ref. Total 
N 
Age (yrs) 
(range) 
 
Males 
N 
Age (yrs) 
 
 
Females 
N 
Age (yrs) 
(range) 
Indications 
for surgery 
Follow-up 
(months) 
(range) 
N of patients on 
remission of 
hyperPRLaemia 
post-operatively 
(%) 
N of patients 
with recurrence 
of 
hyperPRLaemia 
(%) 
 (28) 11 
 
- 
 
DA resistance or 
intolerance 
-a 10 (91%)a - 
 (29)  4 0 4 
(18-35) 
- Mean 
34±13 
4 (100%)b 1/4 (25%)b 
 (30) 39 
Mean 29±9 
- DA resistance or 
intolerance 
Cystic adenoma 
Patient's preference 
- 39 (100%)c - 
(31)d 13 
Mean 37±3e 
- DA resistance or 
intolerance 
Mean 
22±3e 
12 (92%) - 
(32) 7 - DA resistance or 
intolerance 
Patient's preference 
Median 
62 
(8-132)f 
7 (100%)  0/7 (0%) 
(19) 16 - - Mean  
18 
(1-76)f 
13 (81%)g 
 
- 
(33)h 17 - - - 16 (94)h  
(34)i 12 - DA resistance or 
intolerance 
Median  
15 
(4-31)e 
12 (100%)i 0/12 (0%) 
(35)j 28 
Mean 36 
(7-82)e 
- - Median  
54 
(19-54)f 
24 (86%)j - 
 3 
a:  Follow-up data specifically for microprolactinomas are not reported. Remission was defined as normal PRL off 4 
DA in the last follow-up appointment. 5 
b:  Remission was defined as normal PRL 3 months post-operatively. The recurrence in the one patient was 6 
detected 16 months post-operatively. 7 
c:  Remission was defined as normoprolactinaemia on the 7th post-operative day. Information on previous 8 
treatment with DAs and timing of stopping it not available. 9 
d:  The study included 35 patients with prolactinoma (13 with micro- and 22 with macroprolactinoma). Eight 10 
patients had been previously operated but it is not clarified if amongst them there were ones with 11 
microprolactinoma. Information of timing of stopping the DA prior to surgery not available. 12 
e:  Data for both micro- and macroprolactinomas. 13 
f:  Data for all pituitary tumours included in this series. Information on previous treatment with DAs and timing of 14 
stopping it not available. 15 
g:  Remission was defined as normalization of PRL checked at least 6 weeks post-operatively and after withdrawal 16 
of DA during the same period. 17 
h:  The series included 194 patients with 77 functioning and 131 non-functioning pituitary adenomas. Thirty 18 
tumours were operated on after recurrence; there is no information if microprolactinomas were included in this 19 
group. PRL was checked intra-operatively. Information on previous treatment with DAs and timing of stopping it 20 
not available. 21 
i: The study included 25 patients with prolactinoma (12 with micro- and 13 patients with macroprolactinoma). One 22 
of them had undergone prior microscopic transsphenoidal surgery but it was not clarified if this patient had a 23 
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micro- or a macroprolactinoma. Remission was defined as normal PRL the day after surgery. Information on 24 
previous treatment with DAs and timing of stopping it not available. 25 
j: The series included 418 patients with pituitary adenomas, 79 of whom were operated after tumour recurrence; 26 
there was no information if microprolactinomas were included in this group. Remission was defined as normal 27 
PRL levels at the latest check and off DA for at least 2 months. 28 
 29 
 30 
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Table 3. Pituitary function after transsphenoidal surgery for microprolactinomas. 1 
 2 
Ref.  
 
 
N Anterior pituitary  
hormone 
deficits 
Posterior pituitary 
dysfunction 
Microscopic series 
(26) 32 - 5/32 (16%) 
Transient DI 
 
2/32 (6%) 
Permanent DI 
(15)  24 1/24  (4%) a 
Hypogonadotropic 
hypogonadism 
1/24 (4%) b 
Transient 
SIADH 
 (19)  21 0 (0%) - 
(20)  56 0 (0%) - 
(22) 20 0 (0%) - 
(23) 11 5/11 (46%) c 
Hypogonadotropic 
hypogonadism 
(testosterone 
deficiency) 
 
1/11  (9%) d 
Central hypothyroidism 
2/11 (18%) 
Transient DI 
(24) 59 0 (0%) - 
Endoscopic series 
(29) 4 0 (0%) - 
(37) 16 1/16 (6%) 
ACTH and reported 
TSH deficiency 
(diagnosed on 7th 
postoperative day) 
- 
(30) 39 0  (0%) e 1/39 (3%) 
Transient DI 
(19)  16 0 (0%) - 
 3 
a:  Permanent hypogonadotropic hypogonadism despite post-operative normal PRL levels.                   4 
b:  Re-hospitalization was required. 5 
c: Post-operatively, 5 patients were testosterone deficient (central hypogonadism) despite being 6 
normoprolactinaemic (3 after surgery alone and 2 on additional DA therapy).   7 
d:  Post-operatively, central hypothyroidism was reported in one patient but pre-operative assessment was not 8 
available.  9 
e:  No permanent adrenal insufficiency was reported. Adrenal function recovered 6 months after surgery in 29 10 
patients and 18 months after surgery in the remaining ones. 11 
 12 
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